• IHC TESTING

Detectable via IHC Testing

CEACAM5 769 IHC identifies CEACAM5-expressing tumor cells1,2

Detectable via IHC Testing

CEACAM5 769 IHC identifies CEACAM5-expressing tumor cells1,2

IHC testing can be used to determine the percentage of tumor cells that express CEACAM5.1,2 Tumor cells are considered CEACAM5 positive if they exhibit either partial or complete circumferential plasma membrane staining at ≥2+ intensity.1,2

IHC can easily be performed by the pathologist within the current comprehensive biomarker testing workflow alongside other IHC-based biomarkers such as PD-L1.2,3 While this testing should ideally be conducted at the time of diagnosis, IHC can be performed on new or archival biopsy specimens.4

Testing for CEACAM5 expression in tumor cells via IHC may offer a new path forward for patients with advanced NSq NSCLC, though more research is needed.1,2

HIGH EXPRESSION

DEFINED AS ≥2+ STAINING
INTENSITY IN ≥50% OF CELLS

This image features protein expression as determined by CEACAM5 769 IHC. For illustrative purposes only.

MODERATE EXPRESSION

DEFINED AS ≥2+ STAINING
INTENSITY IN 1%-49% OF CELLS

This image features protein expression as determined by CEACAM5 769 IHC. For illustrative purposes only.

LOW EXPRESSION

DEFINED AS 1+ STAINING
INTENSITY IN <1% OF CELLS

This image features protein expression as determined by CEACAM5 769 IHC. For illustrative purposes only.

The CEACAM5 antibody clone, IHC testing protocol, and scoring method may be important considerations in the future to determine CEACAM5 expression.2

The CEACAM5 antibody clone, IHC testing protocol, and scoring method may be important considerations in the future to determine CEACAM5 expression.2

Get answers about
CEACAM5

DOWNLOAD THE CEACAM5 FAQs DOWNLOAD
CEACAM5 FAQs